NASDAQ:TTNP - Titan Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.95 +0.16 (+8.94 %)
(As of 03/20/2019 04:00 PM ET)
Previous Close$1.79
Today's Range$1.81 - $1.95
52-Week Range$1.03 - $8.40
Volume24,998 shs
Average Volume1.73 million shs
Market Capitalization$25.35 million
P/E Ratio-0.45
Dividend YieldN/A
Beta0.69
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.

Receive TTNP News and Ratings via Email

Sign-up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TTNP
CUSIPN/A
Phone650-244-4990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$220,000.00
Book Value$0.24 per share

Profitability

Net Income$-14,300,000.00
Net Margins-168.73%

Miscellaneous

EmployeesN/A
Market Cap$25.35 million
Next Earnings Date4/1/2019 (Estimated)
OptionableOptionable

Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions

What is Titan Pharmaceuticals' stock symbol?

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

When did Titan Pharmaceuticals' stock split? How did Titan Pharmaceuticals' stock split work?

Titan Pharmaceuticals's stock reverse split on the morning of Friday, January 25th 2019. The 1-6 reverse split was announced on Thursday, January 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 24th 2019. An investor that had 100 shares of Titan Pharmaceuticals stock prior to the reverse split would have 17 shares after the split.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) issued its earnings results on Tuesday, August, 14th. The specialty pharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.78) by $0.54. The specialty pharmaceutical company had revenue of $2.67 million for the quarter, compared to analysts' expectations of $0.07 million. Titan Pharmaceuticals had a negative return on equity of 878.37% and a negative net margin of 168.73%. View Titan Pharmaceuticals' Earnings History.

When is Titan Pharmaceuticals' next earnings date?

Titan Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Titan Pharmaceuticals.

What price target have analysts set for TTNP?

1 Wall Street analysts have issued 1-year target prices for Titan Pharmaceuticals' shares. Their predictions range from $12.00 to $12.00. On average, they anticipate Titan Pharmaceuticals' share price to reach $12.00 in the next year. This suggests a possible upside of 515.4% from the stock's current price. View Analyst Price Targets for Titan Pharmaceuticals.

What is the consensus analysts' recommendation for Titan Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Titan Pharmaceuticals.

Has Titan Pharmaceuticals been receiving favorable news coverage?

News coverage about TTNP stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Titan Pharmaceuticals earned a coverage optimism score of 0.7 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the stock's share price in the near term.

Are investors shorting Titan Pharmaceuticals?

Titan Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 1,915,824 shares, an increase of 151.4% from the February 15th total of 762,052 shares. Based on an average trading volume of 3,643,660 shares, the days-to-cover ratio is presently 0.5 days. Approximately 15.4% of the company's shares are sold short. View Titan Pharmaceuticals' Current Options Chain.

Who are some of Titan Pharmaceuticals' key competitors?

What other stocks do shareholders of Titan Pharmaceuticals own?

Who are Titan Pharmaceuticals' key executives?

Titan Pharmaceuticals' management team includes the folowing people:
  • Dr. Marc Rubin, Exec. Chairman (Age 64)
  • Mr. Sunil Bhonsle, CEO, Pres, Principal Financial Officer & Director (Age 69)
  • Dr. Katherine L. Beebe-Devarney Ph.D., Exec. VP & Chief Scientific Officer
  • Mr. Dane D. Hallberg, Exec. VP & Chief Commercial Officer
  • Brian E. Crowley, VP of Fin.

Who are Titan Pharmaceuticals' major shareholders?

Titan Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (2.63%), Geode Capital Management LLC (2.63%) and Virtu Financial LLC (0.30%). Company insiders that own Titan Pharmaceuticals stock include James R Mcnab, Marc Rubin and Sunil Bhonsle. View Institutional Ownership Trends for Titan Pharmaceuticals.

Which major investors are buying Titan Pharmaceuticals stock?

TTNP stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Geode Capital Management LLC and Virtu Financial LLC. Company insiders that have bought Titan Pharmaceuticals stock in the last two years include James R Mcnab, Marc Rubin and Sunil Bhonsle. View Insider Buying and Selling for Titan Pharmaceuticals.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Titan Pharmaceuticals' stock price today?

One share of TTNP stock can currently be purchased for approximately $1.95.

How big of a company is Titan Pharmaceuticals?

Titan Pharmaceuticals has a market capitalization of $25.35 million and generates $220,000.00 in revenue each year. The specialty pharmaceutical company earns $-14,300,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis.

What is Titan Pharmaceuticals' official website?

The official website for Titan Pharmaceuticals is http://www.titanpharm.com.

How can I contact Titan Pharmaceuticals?

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected]


MarketBeat Community Rating for Titan Pharmaceuticals (NASDAQ TTNP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTNP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Featured Article: Blue-Chip Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel